Abstract
Deep vein thrombosis in man presents a considerable clinical challenge. Despite the availability of prophylactic measures, therapeutic thrombolysis is often necessary, but is difficult and hazardous. Treatments have included the administration of plasmin, other less specific proteolytic enzymes, the indirect plasminogen activator, streptokinase, and the direct activators, urokinase and streptokinase–human plasmin complex. All these treatments have been associated with some haemostatic breakdown, which has discouraged their widespread application. The enzyme components of the coagulation and fibrinolytic pathways can, in general, be classed as serine proteases1, with a catalytic mechanism which operates via acyl-enzyme intermediates2. Chase and Shaw3 showed that p-nitrophenyl-p′-guanidinobenzoate could specifically acylate the active centre of trypsin-like enzymes, giving rise to a stable p-guanidinobenzoyl enzyme and other stable acyl-enzymes have since been described4,5. We report here the fibrinolytic use of acylated derivatives of plasmin (E.C.3.4.21.7) and streptokinase–plasmin(ogen) complexes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Griffin, J. H. et al. Meth. Enzym. 45, 56–177 (1976).
Bender, M. L. & Zerner, B. J. Am. chem. Soc. 84, 2550–2555 (1962).
Chase, T. Jr & Shaw, E. Biochem. biophys. Res. Commun. 29, 508–514 (1967).
Chase, T. Jr & Shaw, E. Biochemistry 8, 2212–2224 (1969).
Glover, G., Wang, C.-C. & Shaw, E. J. med. Chem. 16, 262–267 (1973).
Moroi, M. & Aoki, N. J. biol. Chem. 251, 5956–5965 (1976).
Mullertz, S. & Clemmensen, I. Biochem. J. 159, 545–553 (1976).
Barrett, A. J. & Starkey, P. M. Biochem. J. 133, 709–724 (1973).
Sottrup-Jensen, L. et al. in Progress in Chemical Fibrinoly sis and Thrombolysis Vol. 3 (eds Davidson, J. F. et al.) 191–209 (Raven, New York, 1978).
Wiman, B. & Collen, D. Eur. J. Biochem. 84, 573–578 (1978).
Wiman, B. & Collen, D. Nature 272, 549–550 (1978).
Brogden, R. N., Speight, T. M. & Avery, G. S. Drugs 5, 357–445 (1973).
Tanizawa, K., Kasaba, Y. & Kanaoka, Y. J. Am. chem. Soc. 99, 4495–4499 (1977).
McClintock, D. K. & Bell, P. H. Biochem. biophys. Res. Commun. 43, 694–702 (1971).
Smith, R. A. G. Eur. Patent Applic. No. 9879 (1980).
Heene, D. K. & Matthias, F. R. Thromb. Res. 2, 137–154 (1973).
Deutsch, D. D. & Mertz, E. T. Science 170, 1095–1096 (1970).
Wiman, B. & Collen, D. in The Physiological Inhibitors of Coagulation and Fibrinolysis (eds Collen, D. et al.) 145–146 (Elsevier, Amsterdam, 1979).
Mihalyi, E. et al. Biochemistry 15, 5372–5381 (1976).
Friberger, G. et al. in Chromogenic Peptide Substrates (eds Scully, M. F. & Kakkar, V. V.) 121–127 (Churchill-Livingstone, Edinburgh, 1979).
Klöcking, H.-P. in Fibrinolytics and Antifibrinolytics (ed. Markwardt, F.) 151–153 (Springer, Berlin, 1978).
Baillie, A. J. & Sim, A. K. Throm. Diath. haemorrh. 25, 499–506 (1971).
Aber, C. P. et al. Br. med. J. 2, 1100–1104 (1976).
Burmester, H. B. C. et al. J. clin. Path. 23, 43–46 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, R., Dupe, R., English, P. et al. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature 290, 505–508 (1981). https://doi.org/10.1038/290505a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/290505a0
- Springer Nature Limited
This article is cited by
-
Translational initiatives in thrombolytic therapy
Frontiers of Medicine (2017)
-
Activity assessment of microbial fibrinolytic enzymes
Applied Microbiology and Biotechnology (2013)
-
Streptokinase—the drug of choice for thrombolytic therapy
Journal of Thrombosis and Thrombolysis (2007)